CD3 News and Research

RSS

Novavax SARS-CoV-2 vaccine candidate shows promise in animal models

A new study published on the preprint server bioRxiv in June 2020 shows that a candidate spike protein vaccine can induce neutralizing antibodies, antiviral T cell responses, and protection against infection.

2 Jul 2020

Abnormal findings in testicular tissue of COVID-19 patients, SARS-CoV-2 mostly undetected

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused over 9.263 million cases and taken more than 477,000 lives as of June 24, 2020 – just six months after the initial outbreak in Wuhan, China, was reported. The illness, called COVID-19 disease, caused by SARS-CoV-2 is a severe pneumonic illness, caused by the entry of the virus into the type II alveolar cells.

24 Jun 2020

Breakthrough drug significantly delays onset of type 1 diabetes, study finds

Emily Sims, M.D. today shared new findings that a breakthrough drug significantly delays the onset of type 1 diabetes (T1D).

15 Jun 2020

Immunotherapy before surgery may help eradicate high-risk breast cancer

A new study led by Yale Cancer Center researchers shows women with high-risk HER2-negative breast cancer treated before surgery with immunotherapy, plus a PARP inhibitor with chemotherapy, have a higher rate of complete eradication of cancer from the breast and lymph nodes compared to chemotherapy alone.

28 Apr 2020

Ludwig Cancer Research study develops a safer CAR-T therapy

A Ludwig Cancer Research study has devised a new type of chimeric antigen-receptor (CAR) T cell-;a family of promising immunotherapies for cancer- that can be switched on and off on demand.

3 Feb 2020

IONTAS antibody for the treatment of B-Cell ALL receives approval for clinical trials

IONTAS Limited, a leader in the discovery and optimization of fully human antibodies, has been informed that International Biotechnology Center Generium, a leading Russian biopharmaceutical company, focused on developing and commercializing pharmaceutical products for the treatment of orphan diseases and cancer, has received approval from the Russian Health Authorities to initiate clinical trials with its CD3/CD19 bispecific antibody for the treatment of B-Cell Acute Lymphoblastic Leukemia.

From FairJourney Biologics 11 Dec 2019

Immunotherapy more effective than chemotherapy for children, young adults with relapsed B-ALL

New findings from a clinical trial show that treatment with the immunotherapy drug blinatumomab is superior to standard chemotherapy for children and young adults with high- or intermediate-risk B-cell acute lymphoblastic leukemia that has relapsed.

10 Dec 2019

New cellular immunotherapy for cancers

A new study published in the journal Nature Communications on 22 October 2019 reports a new approach to cancer treatment that increases the immune capability of T lymphocytes against malignant cancers. This allows the T cells to successfully infiltrate and destroy these tumors. Animal trials have been completed and the researchers are planning clinical trials in human beings next.

26 Oct 2019

Virus employs powerful strategy to inhibit natural killer cell function

The virus responsible for chickenpox and shingles employs a powerful strategy of immune evasion, inhibiting the ability of natural killer cells to destroy infected cells and produce molecules that help control viral infection, according to a study published June 13 in the open-access journal PLOS Pathogens by Allison Abendroth of the Discipline of Infectious Diseases and Immunology in the Charles Perkins Centre at the University of Sydney, and colleagues.

From PLOS ONE 14 Jun 2019

Drug that targets the immune system can delay type 1 diabetes in high risk children, adults

A drug that targets the immune system can delay the onset of type 1 diabetes an average of two years in children and adults at high risk, according to findings from TrialNet's Teplizumab (anti-CD3) Prevention Study published in the New England Journal of Medicine.

10 Jun 2019

Moffitt researchers shed light on how CAR T cells function mechanistically

The scientific community has made great strides over the past decade in the development of a new class of cancer therapy called immunotherapy, a treatment that activates a patient's own immune system to target cancer cells.

15 Feb 2019

AbbVie, Teneobio enter into strategic transaction to develop potential treatment for multiple myeloma

AbbVie, Teneobio, Inc. and its affiliate TeneoOne, Inc. announced today that they have entered a global strategic transaction to develop and commercialize TNB-383B, a BCMA-targeting immunotherapeutic for the potential treatment of multiple myeloma.

12 Feb 2019

Lymph nodes serve as reservoirs of prolonged bacterial persistence during Mtb infection

Lymph nodes can contain large numbers of tuberculosis-causing bacteria and serve as long-term reservoirs of bacterial persistence, according to a study published November 1 in the open-access journal PLOS Pathogens by JoAnne Flynn of the University of Pittsburgh School of Medicine, and colleagues.

2 Nov 2018

Study shows how machinery within immune system activates T cells to attack cancer

In just a few years, CAR T-cell and other adoptive T-cell therapies have emerged as among the most promising forms of cancer immunotherapy.

31 Oct 2018

FDA grants accelerated approval to leukemia drug for patients with MRD-positive ALL

The U.S. Food and Drug Administration granted accelerated approval to Blincyto (blinatumomab) to treat adults and children with B-cell precursor acute lymphoblastic leukemia (ALL) who are in remission but still have minimal residual disease (MRD).

30 Mar 2018

Novel oncolytic virus expressing BiTE molecule elicits T cell-mediated killing of tumor cells

In a research article published in EMBO Molecular Medicine, a group of scientists at the University of Oxford have described a new twist on cancer immunotherapy, combining two independent cell killing approaches in a single therapeutic with high potency and broad applicability.

13 Mar 2018

Excess weight linked to higher degree of synovitis in RA patients

Excess weight is linked to a higher degree of synovitis in people with rheumatoid arthritis and can affect their treatment response, according to new research findings presented this week at the 2017 ACR/ARHP Annual Meeting in San Diego.

6 Nov 2017

Activated T-cells promote heart failure after heart attack

Chronic inflammation after a heart attack can promote heart failure and death. University of Alabama at Birmingham researchers have now shown that activated T-cells — part of the immune system's inflammatory response — are both necessary and sufficient to produce such heart failure.

28 Feb 2017

Fred Hutch’s new Evergreen Fund to promote commercialization of research into lifesaving therapies

Fred Hutchinson Cancer Research Center announced its first-ever grants from its newly established Evergreen Fund to spur researchers' efforts to advance bold ideas toward creating or partnering with a commercial entity.

28 Dec 2016

Analysis of biopsies during early treatment predicts patient’s response to melanoma immunotherapy

Immune response measured in tumor biopsies during the course of early treatment predicts which melanoma patients will benefit from specific immune checkpoint blockade drugs, researchers at The University of Texas MD Anderson Cancer Center report in the journal Cancer Discovery.

11 Aug 2016